Back to top

Mixed Trial Results Shape Outlook for AstraZeneca Stock

AstraZeneca ($AZN) said its asthma drug Fasenra failed to hit the main target in a late trial for chronic obstructive pulmonary disease, or COPD. T...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)